In last trading session, Cullinan Therapeutics Inc (NASDAQ:CGEM) saw 0.38 million shares changing hands with its beta currently measuring -0.09. Company’s recent per share price level of $17.98 trading at $0.05 or 0.28% at ring of the bell on the day assigns it a market valuation of $1.04B. That closing price of CGEM’s stock is at a discount of -67.91% from its 52-week high price of $30.19 and is indicating a premium of 57.51% from its 52-week low price of $7.64. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.5 million shares which gives us an average trading volume of 792.71K if we extend that period to 3-months.

For Cullinan Therapeutics Inc (CGEM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.78 in the current quarter.

Cullinan Therapeutics Inc (NASDAQ:CGEM) trade information

Upright in the green during last session for gaining 0.28%, in the last five days CGEM remained trading in the red while hitting it’s week-highest on Tuesday, 09/03/24 when the stock touched $17.98 price level, adding 9.6% to its value on the day. Cullinan Therapeutics Inc’s shares saw a change of 76.45% in year-to-date performance and have moved -4.67% in past 5-day. Cullinan Therapeutics Inc (NASDAQ:CGEM) showed a performance of 8.71% in past 30-days. Number of shares sold short was 8.16 million shares which calculate 10.48 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 30 to the stock, which implies a rise of 40.07% to its current value. Analysts have been projecting 28 as a low price target for the stock while placing it at a high target of 38. It follows that stock’s current price would drop -55.73% in reaching the projected high whereas dropping to the targeted low would mean a loss of -55.73% for stock’s current value.

Cullinan Therapeutics Inc (CGEM) estimates and forecasts

Statistics highlight that Cullinan Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 9.97% of value to its shares in past 6 months, showing an annual growth rate of 13.28% while that of industry is 17.90. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -62.42% during past 5 years.

Cullinan Therapeutics Inc (NASDAQ:CGEM)’s Major holders

Insiders are in possession of 4.51% of company’s total shares while institution are holding 115.25 percent of that, with stock having share float percentage of 120.69%. Investors also watch the number of corporate investors in a company very closely, which is 115.25% institutions for Cullinan Therapeutics Inc that are currently holding shares of the company. BIOIMPACT CAPITAL LLC is the top institutional holder at CGEM for having 7.65 million shares of worth $133.39 million. And as of 2024-06-30, it was holding 17.7821 of the company’s outstanding shares.

The second largest institutional holder is BVF INC/IL, which was holding about 5.75 million shares on 2024-06-30. The number of shares represents firm’s hold over 13.3703 of outstanding shares, having a total worth of $100.29 million.